Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
Status:
Terminated
Trial end date:
2017-06-02
Target enrollment:
Participant gender:
Summary
The purpose of the protocol is evaluate the safety, the pharmacodynamics and the
pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.